An Annapolis company that hopes to create a non-drug treatment for migraine and mood disorders has raised $4 million of a $7 million series A round.

The funding round will help Mi-Helper conduct clinical studies to get U.S. Food and Drug Administration clearance for its eponymous device. Mi-Helper has already gone through clinical studies at the Mayo Clinic, Michigan State University and Atrium Health and CEO Steve Schaefer plans for the device to hit the market in 2024. The company is planning to conduct a large at-home study to see if patients will be able to use the device at home instead of at a doctor’s office.

Release date